Journal of Urban Health

, Volume 90, Issue 2, pp 323–328 | Cite as

Adherence to Chronic Disease Medications among New York City Medicaid Participants

  • Kelly A. Kyanko
  • Robert H. Franklin
  • Sonia Y. Angell
Article

Abstract

Medication adherence is critical for cardiovascular disease prevention and control. Local health departments are well positioned to address adherence issues, however relevant baseline data and a mechanism for monitoring impact of interventions are lacking. We performed a retrospective analysis using New York State Medicaid claims from 2008 to 2009 to describe rates and predictors of adherence among New York City Medicaid participants with dyslipidemia, diabetes, or hypertension. Adherence was measured using the medication possession ratio, and multivariable logistic regression was used to assess factors related to adherence. Medication regimen adherence was 63%. Greater adherence was observed in those who were older, male, and taking medications from ≥3 drug classes. Compared with whites, blacks and Hispanics were less likely to be adherent (adjusted odds ratio [OR]=0.67, 95% confidence interval [CI]: 0.65–0.70 and adjusted OR=0.76, 95% CI: 0.73–0.78, respectively), while Asians were as likely. Medication adherence was inadequate and racial disparities were identified in NYC Medicaid participants on stable medication regimens for chronic disease. This study demonstrates a claims-based model that may be used by local health departments to monitor and evaluate efforts to improve adherence and reduce disparities.

Keywords

Medication adherence Health disparities Cardiovascular prevention Public health 

References

  1. 1.
    Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. [Review] [79 refs]. Circulation. 2009; 119(23): 3028–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Svc Res. 2007; 7: 175.CrossRefGoogle Scholar
  3. 3.
    Steiner JF, Robbins LJ, Roth SC, Hammond WS. The effect of prescription size on acquisition of maintenance medications. J Gen Intern Med. 1993; 8(6): 306–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011; 171(9): 814–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. New Engl J Med. 2010; 362(17): 1553–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000; 40(2): 157–65.Google Scholar
  7. 7.
    Center for Medicare and Medicaid Services. 2011 Medicare Part D Medication Therapy (MTM) Programs. Available at: http://www.cms.gov/PrescriptionDrugCovContra/Downloads/MTMFactSheet2011063011Final.pdf. Accessed 1 May 2012
  8. 8.
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50(1): 105–16.PubMedCrossRefGoogle Scholar
  9. 9.
    Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988; 26(8): 814–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Schectman JM, Bovbjerg VE, Voss JD. Predictors of medication-refill adherence in an indigent rural population. Med Care. 2002; 40(12): 1294–300.PubMedCrossRefGoogle Scholar
  11. 11.
    Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006; 47(6): 1039–48.PubMedCrossRefGoogle Scholar
  12. 12.
    Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5): 487–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010; 25(6): 495–503.PubMedCrossRefGoogle Scholar
  15. 15.
    Traylor AH, Schmittdiel JA, Uratsu CS, Mangione CM, Subramanian U. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med. 2010; 25(11): 1172–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010; 48(3) 196–202.Google Scholar
  17. 17.
    Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 2009; 101(1): 34–9.PubMedGoogle Scholar
  18. 18.
    Shenolikar RA, Balkrishnan R, Camacho FT, Whitmire JT, Anderson RT. Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Natl Med Assoc. 2006; 98(7): 1071–7.PubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 2012

Authors and Affiliations

  • Kelly A. Kyanko
    • 1
  • Robert H. Franklin
    • 2
  • Sonia Y. Angell
    • 3
    • 4
  1. 1.Department of Population HealthNew York University School of MedicineNew YorkUSA
  2. 2.New York State Department of HealthAlbanyUSA
  3. 3.New York City Department of Health and Mental HygieneNew YorkUSA
  4. 4.Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations